Website under construction following recent changes to clinical trial program to incorporate IHL-675A that is under
investigation for the treatment of sepsis associated ARDS, the leading cause of death associated with COVID-19

Impression Healthcare

A cannabinoid medicines development company undertaking extensive clinical programs, guided by our medical advisory board.

Therapeutic products under development, and patent protection strategies, have no existing pharmacotherapy treatments available to patients, representing global market opportunities.

Clinical programs are informed by existing bodies of research, underpinning our procession to in-human trials.

 Impression also has its Australian licenses in place to import, export and distribute medicinal cannabis products.

We’ve launched our own line of pharmaceutical grade cannabinoid products under the brand name Incannex Pharmaceuticals.

Incannex formulations have been designed to match those product-types that are most in-demand.

Board and Management

Impression Healthcare logo

Want The Latest From IHL?

Join our investor mailing list to be notified of announcements when they are made and sent all the latest investor materials as they are published. 

Thanks for signing up! We'll be in touch shortly.